Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Clinical trial NCT02485691 · COMPLETED

Trial details

NCT number: NCT02485691
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Prostate Cancer Metastatic

Start date: 2015-11-09
Primary completion: 2019-03-27
Enrollment: 255

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.